Lenalidomide, with chemical name of 3-(7- amino -3- oxo-1H- isoindole -2- yl) piperidine -2,6-dione and molecular formula of C 13H 13N3O3, is an anti-tumor drug developed by Celgene biopharmaceutical company in the United States. The chemical structure of lenalidomide is similar to thalidomide. Although the exact mechanism of action of lenalidomide is not clear, it is known that lenalidomide has immunomodulatory and antiangiogenic effects. After oral administration, lenalidomide is quickly absorbed by human body. In vitro experiments showed that the plasma protein binding rate of lenalidomide was about 30%. About 2/3 of lenalidomide is excreted in urine in its original form, and its elimination half-life is about 3 hours.